Thomas J Müller, Arnaud Künzi, Ellen Heitlinger, Bernd Krämer, Roland von Känel, Josef Hättenschwiler, Matthias Hilpert, Christian Imboden, Edith Holsboer-Trachsler, Martin Hatzinger, Siegfried Kasper, Borwin Bandelow, Erich Seifritz
{"title":"抗焦虑药物治疗焦虑症的比较疗效和可接受性:一项系统综述和网络荟萃分析。","authors":"Thomas J Müller, Arnaud Künzi, Ellen Heitlinger, Bernd Krämer, Roland von Känel, Josef Hättenschwiler, Matthias Hilpert, Christian Imboden, Edith Holsboer-Trachsler, Martin Hatzinger, Siegfried Kasper, Borwin Bandelow, Erich Seifritz","doi":"10.1007/s00406-025-02082-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Anti-anxiety medications' side effects and dependency risks necessitate thorough consideration of their efficacy and acceptability when making treatment decisions.</p><p><strong>Methods: </strong>A systematic review and Network Meta-Analysis (NMA) was conducted using three databases from 1980 to 2020, focusing on adults diagnosed with generalized anxiety disorder (GAD) or any relevant diagnostic classification of anxiety disorder or those for whom Hamilton Anxiety (HAM-A) data is available, and including any comparator (placebo and/or active comparator treatments). The primary outcomes were efficacy (mean difference in change from baseline in HAM-A total score) and acceptability (study discontinuations for any cause). This study is registered with Open Science Framework (OSF) database.</p><p><strong>Findings: </strong>Analysis of 100 trials involving 28,637 participants showed that most active drugs were more effective than placebo in reducing anxiety. Notably, silexan was the only phytopharmaceutical included in the NMA. Clomipramine had the highest efficacy and vortioxetine the least. However, in terms of acceptability, clomipramine led to the most study discontinuations, while clobazam had the lowest discontinuation rate, indicating that efficacy and acceptability do not always align. Notably, silexan was both highly effective and as acceptable as a placebo. Only four treatments showed fewer adverse events than placebo (diazepam, agomelatine, clobazam, and silexan).</p><p><strong>Conclusion: </strong>This network meta-analysis provides a unique comparison of the efficacy and acceptability of anxiolytics. It represents one of the most comprehensive evidence bases available to guide the first choice of treatment for anxiety disorders in adults.</p>","PeriodicalId":11822,"journal":{"name":"European Archives of Psychiatry and Clinical Neuroscience","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparative efficacy and acceptability of anxiolytic drugs for the treatment of anxiety disorders: a systematic review and network meta-analysis.\",\"authors\":\"Thomas J Müller, Arnaud Künzi, Ellen Heitlinger, Bernd Krämer, Roland von Känel, Josef Hättenschwiler, Matthias Hilpert, Christian Imboden, Edith Holsboer-Trachsler, Martin Hatzinger, Siegfried Kasper, Borwin Bandelow, Erich Seifritz\",\"doi\":\"10.1007/s00406-025-02082-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Anti-anxiety medications' side effects and dependency risks necessitate thorough consideration of their efficacy and acceptability when making treatment decisions.</p><p><strong>Methods: </strong>A systematic review and Network Meta-Analysis (NMA) was conducted using three databases from 1980 to 2020, focusing on adults diagnosed with generalized anxiety disorder (GAD) or any relevant diagnostic classification of anxiety disorder or those for whom Hamilton Anxiety (HAM-A) data is available, and including any comparator (placebo and/or active comparator treatments). The primary outcomes were efficacy (mean difference in change from baseline in HAM-A total score) and acceptability (study discontinuations for any cause). This study is registered with Open Science Framework (OSF) database.</p><p><strong>Findings: </strong>Analysis of 100 trials involving 28,637 participants showed that most active drugs were more effective than placebo in reducing anxiety. Notably, silexan was the only phytopharmaceutical included in the NMA. Clomipramine had the highest efficacy and vortioxetine the least. However, in terms of acceptability, clomipramine led to the most study discontinuations, while clobazam had the lowest discontinuation rate, indicating that efficacy and acceptability do not always align. Notably, silexan was both highly effective and as acceptable as a placebo. Only four treatments showed fewer adverse events than placebo (diazepam, agomelatine, clobazam, and silexan).</p><p><strong>Conclusion: </strong>This network meta-analysis provides a unique comparison of the efficacy and acceptability of anxiolytics. It represents one of the most comprehensive evidence bases available to guide the first choice of treatment for anxiety disorders in adults.</p>\",\"PeriodicalId\":11822,\"journal\":{\"name\":\"European Archives of Psychiatry and Clinical Neuroscience\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-08-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Archives of Psychiatry and Clinical Neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00406-025-02082-0\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Archives of Psychiatry and Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00406-025-02082-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Comparative efficacy and acceptability of anxiolytic drugs for the treatment of anxiety disorders: a systematic review and network meta-analysis.
Background: Anti-anxiety medications' side effects and dependency risks necessitate thorough consideration of their efficacy and acceptability when making treatment decisions.
Methods: A systematic review and Network Meta-Analysis (NMA) was conducted using three databases from 1980 to 2020, focusing on adults diagnosed with generalized anxiety disorder (GAD) or any relevant diagnostic classification of anxiety disorder or those for whom Hamilton Anxiety (HAM-A) data is available, and including any comparator (placebo and/or active comparator treatments). The primary outcomes were efficacy (mean difference in change from baseline in HAM-A total score) and acceptability (study discontinuations for any cause). This study is registered with Open Science Framework (OSF) database.
Findings: Analysis of 100 trials involving 28,637 participants showed that most active drugs were more effective than placebo in reducing anxiety. Notably, silexan was the only phytopharmaceutical included in the NMA. Clomipramine had the highest efficacy and vortioxetine the least. However, in terms of acceptability, clomipramine led to the most study discontinuations, while clobazam had the lowest discontinuation rate, indicating that efficacy and acceptability do not always align. Notably, silexan was both highly effective and as acceptable as a placebo. Only four treatments showed fewer adverse events than placebo (diazepam, agomelatine, clobazam, and silexan).
Conclusion: This network meta-analysis provides a unique comparison of the efficacy and acceptability of anxiolytics. It represents one of the most comprehensive evidence bases available to guide the first choice of treatment for anxiety disorders in adults.
期刊介绍:
The original papers published in the European Archives of Psychiatry and Clinical Neuroscience deal with all aspects of psychiatry and related clinical neuroscience.
Clinical psychiatry, psychopathology, epidemiology as well as brain imaging, neuropathological, neurophysiological, neurochemical and moleculargenetic studies of psychiatric disorders are among the topics covered.
Thus both the clinician and the neuroscientist are provided with a handy source of information on important scientific developments.